Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem, Inc. (Nasdaq:VSTM) has sold its oral cancer drug COPIKTRA to Secura Bio for $70 million in cash, with potential additional earnings reaching $311 million based on regulatory and sales milestones. The company will also receive low double-digit royalties for U.S., European, and UK sales exceeding $100 million. This strategic move allows Verastem to focus on developing its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) programs targeting KRAS mutant solid tumors. The ongoing FRAME study shows promise, with registration-directed trials planned.